参考文献/References:
[1].尹智明,余朝文.下肢动脉硬化闭塞症腔内介入治疗的研究进展[J].中国普通外科杂志, 2017, 26(6):789-794.
[2].王深明,姚陈.下肢动脉硬化闭塞症血管腔内治疗热点问题[J].中国实用外科杂志, 2016, 36(12):1253-1255.
[3].Aboyans V, Sevestre MA, Désormais I, et al. Epidemiology of lower extremity artery disease[J]. Presse Med,2018, 47(1):38-46.
[4].苏苗苗,陈忠.股腘动脉粥样硬化性闭塞症的腔内治疗进展[J].心肺血管病杂志, 2015, 34(2):150-153.
[5].Hess CN,Rogers RK,Wang TY,et al.Major adverse limb events and 1-year outcomes after peripheral artery revascularization[J].J Am Coll Cardiol,2018, 72(9):999-1011.
[6].吴彧,孙琳,黄彦生,等.氧化应激与炎症在动脉粥样硬化发生发展中的作用及相关治疗药物研究[J].中国实用神经疾病杂志,2014, 17(21):127-129.
[7].Rein P,Saely CH,Silbernagel G,et al.Systemic inflammation is higher in peripheral artery disease than in stable coronary artery disease[J].Atherosclerosis, 2015, 239(2) :299-303.
[8].司可,刘汉凝,孙骋,等.巨噬细胞在冠状动脉粥样硬化过程中作用及机制研究现况[J].中国分子心脏病学杂志,2018,18(6):2704-2707.
[9].Sun X,Guo S,Yao J,et al.Rapid inhibition of atherosclerotic plaque progression by sonodynamic therapy[J]. Cardiovasc Res,2019,115(1):190-203.
[10].Kure K,Sato H,Aoyama N,et al.Accelerated inflammation in peripheral artery disease patients with periodontitis[J]. J Periodontal Implant Sci,2018,48(6):337-346.
[11].Mizzi A,Cassar K,Bowen C,et al. The progression rate of peripheral arterial disease in patients with intermittent claudication:a systematic review[J]. J Foot Ankle Res,2019,12:40.
[12].刘永东.动脉硬化闭塞症患者早期介入治疗与机体炎症反应机制的研究进展[J].解放军预防医学杂志,2018, 36(4):540-543.
[13].王建旗,史旭波,马长生,等.炎症预测和预防动脉粥样硬化性心血管事件的研究进展[J].心血管病学进展,2018,39(5):687-690.
[14].Rosenfield K,Jaff MR,White CJ,et al.Trial of a paclitaxel-coated balloon for femoropopliteal artery disease[J]. N Engl J Med,2015, 373(2):145-53.
[15].Stavroulakis K,Torsello G, Manal A, et al. Results of primary stent therapy for femoropopliteal peripheral arterial disease at 7 years[J]. J Vasc Surg,2016, 64(6):1696-1702.
[16].Dopheide JF,Rubrech J,Trumpp A,et al.Supervised exercise training in peripheral arterial disease increases vascular shear stress and profunda femoral artery diameter[J]. Eur J Prev Cardiol,2017, 24(2):178-191.
[17].Dopheide JF,Rubrech J,Trumpp A,et al.Supervised exercise training in peripheral arterial disease increases vascular shear stress and profunda femoral artery diameter[J]. Eur J Prev Cardiol,2017, 24(2):178-191.
[18].Laird A,Schneider A,Jaff R,et al. Long-term clinical effectiveness of a drug-coated balloon for the treatment of femoropopliteal lesions:five-year outcomes from the IN.PACT SFA randomized trial[J]. Circ Cardiovasc Interv,2019, 12(6):e007702
[19].褚现明,李冰,安毅,等.炎症与动脉粥样硬化关系研究进展[J].中国分子心脏病学杂志,2010,10(3):184-188.
[20].Morrow DA, de Lemos JA, Sabatine MS, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial[J]. Circulation,2006, 114(4):281-288.
[21].Antonopoulos AS, Papanikolaou E, Vogiatzi G, et al. Anti-inflammatory agents in peripheral arterial disease[J]. Curr Opin Pharmacol,2018, 39 :1-8.
[22].Vucic E, Calcagno C, Dickson SD, et al. Regression of inflammation in atherosclerosis by the LXR agonist R211945:a noninvasive assessment and comparison with atorvastatin[J]. JACC Cardiovasc Imaging,2012, 5(8):819-828.
[23].Li Y, Zhou Q, Hu Z, et al. 5-Aminolevulinic acid-based sonodynamic therapy induces the apoptosis of osteosarcoma in mice[J]. PLoS One,2015, 10(7):e0132074.
[24].王巍,程佳丽,孙鑫,等. 5-氨基酮戊酸介导的声动力疗法诱导巨噬细胞和泡沫细胞凋亡[J]. 中国动脉硬化杂志,2016, 24(4):339-344.
[25].Sun X,Guo S,Yao J,et al.Rapid inhibition of atherosclerotic plaque progression by sonodynamic therapy[J]. Cardiovasc Res,2019, 115(1):190-203.
[26].[26]李贺,田野,田振. 声动力疗法引起的细胞自噬在肿瘤和动脉粥样硬化中的研究进展[J]. 基础医学与临床,2018, 38(11):1620-1624.
相似文献/References:
[1]胥雪莲,何川.炎症与动脉粥样硬化[J].心血管病学进展,2015,(5):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
XU Xuelian,HE Chuan.Inflammation and Atherosclerosis[J].Advances in Cardiovascular Diseases,2015,(2):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
[2]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(2):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[3]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(2):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[4]宋志平 杨永健.GPR 35在心血管疾病中的研究进展[J].心血管病学进展,2019,(9):1304.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.031]
SONG Zhiping,YANG Yongjian.The Current Progress of GPR 35 in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(2):1304.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.031]
[5]顾佳仪 刘正霞 鲁翔.白介素-1β在冠心病中的研究进展[J].心血管病学进展,2020,(2):125.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.006]
Gu Jiayi,Liu Zhengxia,Lu Xiang.Interleukin-1 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(2):125.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.006]
[6]严宁,杨春霞,马娟,等.β-谷甾醇对大鼠心肌缺血再灌注损伤和ERK1/2信号通路的影响[J].心血管病学进展,2020,(3):321.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.026]
YAN Ning,YANG Chunxia,MA Juan,et al.Effects of -sitosterolon Myocardial Ischemia-reperfusion Injury and ERK1/2 Signaling Pathway in Rats[J].Advances in Cardiovascular Diseases,2020,(2):321.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.026]
[7]韩月 朱莉 宋桂仙.白介素-12家族在冠状动脉粥样硬化中的研究进展[J].心血管病学进展,2020,(5):508.[doi:10.16806/j.cnki.issn.1004-3934.20.05.016]
HAN Yue,ZHU Li,SONG Guixian.Interleukin-12 Family in Coronary Atherosclerosis[J].Advances in Cardiovascular Diseases,2020,(2):508.[doi:10.16806/j.cnki.issn.1004-3934.20.05.016]
[8]汪汉,刘汉雄,蔡琳.2019冠状病毒病的心血管表现[J].心血管病学进展,2020,(11):1152.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
WANG Han,LIU Hanxiong,CAI Lin.Cardiovascular Profiles in Corona V irus Disease 2019[J].Advances in Cardiovascular Diseases,2020,(2):1152.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[9]张颖怡 刘金波 刘欢 赵娜 赵红薇 王宏宇.全身动脉粥样硬化斑块与脑梗死的关系：北京血管病变评价研究结果[J].心血管病学进展,2021,(3):277.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.020]
ZHANG YingyiLIU J inboLIU HuanZHAO NaZHAO HongweiWANG Hongyu.The Relationship Between Systematic Atherosclerotic Plaques and Cerebral Infarction:Results from Beijing Vascular Disease Evaluation Study[J].Advances in Cardiovascular Diseases,2021,(2):277.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.020]
[10]李佳珊 关秀茹.ABCA1：调控胆固醇逆向转运与炎症激活之间关系的研究新进展[J].心血管病学进展,2021,(7):649.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.018]
LI Jiashan,GUAN Xiuru.ABCA1: New Progress in Regulating the Relationship Between Cholesterol Reverse Transport and Inflammation Activation[J].Advances in Cardiovascular Diseases,2021,(2):649.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.018]